JP2002542300A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542300A5 JP2002542300A5 JP2000613464A JP2000613464A JP2002542300A5 JP 2002542300 A5 JP2002542300 A5 JP 2002542300A5 JP 2000613464 A JP2000613464 A JP 2000613464A JP 2000613464 A JP2000613464 A JP 2000613464A JP 2002542300 A5 JP2002542300 A5 JP 2002542300A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- nucleic acid
- acid sequence
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 16
- 150000007523 nucleic acids Chemical group 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 8
- 206010016654 Fibrosis Diseases 0.000 description 7
- 230000004761 fibrosis Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 208000007122 AIDS-Associated Nephropathy Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000009209 Familial cutaneous collagenoma Diseases 0.000 description 1
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
- 206010070737 HIV associated nephropathy Diseases 0.000 description 1
- 102100025323 Integrin alpha-1 Human genes 0.000 description 1
- 108010041341 Integrin alpha1 Proteins 0.000 description 1
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- 208000000185 Localized scleroderma Diseases 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13084799P | 1999-04-22 | 1999-04-22 | |
| US60/130,847 | 1999-04-22 | ||
| US13721499P | 1999-06-01 | 1999-06-01 | |
| US60/137,214 | 1999-06-01 | ||
| PCT/US2000/010781 WO2000064474A1 (en) | 1999-04-22 | 2000-04-21 | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007080371A Division JP2007182453A (ja) | 1999-04-22 | 2007-03-26 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
| JP2014007898A Division JP2014065747A (ja) | 1999-04-22 | 2014-01-20 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002542300A JP2002542300A (ja) | 2002-12-10 |
| JP2002542300A5 true JP2002542300A5 (cg-RX-API-DMAC7.html) | 2007-05-31 |
| JP5483515B2 JP5483515B2 (ja) | 2014-05-07 |
Family
ID=26828876
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000613464A Expired - Fee Related JP5483515B2 (ja) | 1999-04-22 | 2000-04-21 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
| JP2007080371A Pending JP2007182453A (ja) | 1999-04-22 | 2007-03-26 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
| JP2014007898A Withdrawn JP2014065747A (ja) | 1999-04-22 | 2014-01-20 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007080371A Pending JP2007182453A (ja) | 1999-04-22 | 2007-03-26 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
| JP2014007898A Withdrawn JP2014065747A (ja) | 1999-04-22 | 2014-01-20 | インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法 |
Country Status (31)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2243259T3 (es) * | 1999-04-22 | 2005-12-01 | Biogen Idec Ma Inc. | Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina. |
| EP1181054A1 (en) | 1999-06-01 | 2002-02-27 | Biogen, Inc. | A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders |
| UA73300C2 (en) * | 1999-06-01 | 2005-07-15 | Biogen Inc | Use of composition containing homolog of antibody antagonizing interaction between integrin with alpha-4 subunit and its ligand for treating fibrosis |
| GB0013674D0 (en) * | 1999-06-08 | 2000-07-26 | Lorantis Ltd | Therapeutic use |
| US20020013300A1 (en) * | 2000-03-17 | 2002-01-31 | Avocet Polymer Technologies, Inc. | Methods for improving size and appearance of a wound |
| AU2002225878A1 (en) * | 2000-11-02 | 2002-05-15 | Smith Kline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| EP1423431B1 (en) * | 2001-04-13 | 2010-06-16 | Biogen Idec MA Inc. | Antibodies to vla-1 |
| US20030154499A1 (en) * | 2001-06-08 | 2003-08-14 | Monika Wasel-Nielen | Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor |
| US20050043272A1 (en) * | 2003-07-11 | 2005-02-24 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
| US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| JP5037134B2 (ja) * | 2003-10-17 | 2012-09-26 | レハブ アル−ジャマル | 組織修復 |
| US20070078109A1 (en) * | 2004-02-13 | 2007-04-05 | David Platt | Compositions and methods used to treat acne and candida |
| WO2006017417A2 (en) * | 2004-08-02 | 2006-02-16 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
| CA2652815C (en) * | 2006-05-25 | 2015-12-15 | Biogen Idec Ma Inc. | Methods of treating stroke |
| CA2693310C (en) | 2007-08-02 | 2018-11-27 | Arresto Biosciences, Inc. | Lox and loxl2 inhibitors, antibodies and uses thereof |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| CA2875200C (en) * | 2012-03-28 | 2024-02-20 | Hiroshima University | Fibrosis suppression by inhibiting integrin alpha8beta1 function |
| US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
| JP7315566B2 (ja) * | 2018-02-23 | 2023-07-26 | 中外製薬株式会社 | 種交差性抗潜在型ＴＧＦ－β１抗体および使用方法 |
| CN120022360A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| EP4720125A1 (en) | 2023-05-30 | 2026-04-08 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| EP4762093A1 (en) | 2023-08-14 | 2026-06-24 | Paragon Therapeutics, Inc. | Alpha 4 beta 7 integrin binding proteins and methods of use |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) * | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| CA2127462C (en) * | 1992-01-13 | 1999-03-23 | Roy R. Lobb | Treatment for asthma |
| SG44845A1 (en) | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| WO1994017828A2 (en) * | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| DE69535133T2 (de) * | 1994-01-25 | 2008-08-21 | Elan Pharmaceuticals, Inc., San Francisco | Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4 |
| ATE195428T1 (de) * | 1994-04-26 | 2000-09-15 | Kanebo Ltd | Arznei für rheumatoide arthritis |
| GB9519667D0 (en) * | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| EP0827742A1 (en) * | 1996-09-04 | 1998-03-11 | Vrije Universiteit Brussel | Use of histone deacetylase inhibitors for treating fribosis or cirrhosis |
| JPH10330268A (ja) * | 1997-05-26 | 1998-12-15 | Kureha Chem Ind Co Ltd | ピラノピラノン化合物含有ｈｓｐ４７合成抑制剤 |
| NZ502546A (en) * | 1997-08-08 | 2002-02-01 | Univ California | Treatment of acute lung injury and fibrosis with antibodies to alpha-v-beta-6 |
| US6492325B1 (en) * | 1998-05-22 | 2002-12-10 | Boys Town National Research Hospital | Use of α1β1 integrin receptor inhibitors and TGF-β1 inhibitors in the treatment of kidney disease |
| ES2243259T3 (es) * | 1999-04-22 | 2005-12-01 | Biogen Idec Ma Inc. | Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina. |
| TW201718598A (zh) * | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
-
2000
- 2000-04-21 ES ES00926238T patent/ES2243259T3/es not_active Expired - Lifetime
- 2000-04-21 AU AU44800/00A patent/AU783054B2/en not_active Ceased
- 2000-04-21 HK HK02103238.4A patent/HK1041452B/en not_active IP Right Cessation
- 2000-04-21 HU HU0201015A patent/HU226383B1/hu not_active IP Right Cessation
- 2000-04-21 KR KR1020077006991A patent/KR100837715B1/ko not_active Expired - Fee Related
- 2000-04-21 EA EA200101116A patent/EA006681B1/ru not_active IP Right Cessation
- 2000-04-21 WO PCT/US2000/010781 patent/WO2000064474A1/en not_active Ceased
- 2000-04-21 BR BR0010669-0A patent/BR0010669A/pt not_active Application Discontinuation
- 2000-04-21 KR KR1020017013313A patent/KR100746522B1/ko not_active Expired - Fee Related
- 2000-04-21 MX MXPA01010612A patent/MXPA01010612A/es active IP Right Grant
- 2000-04-21 RS RSP-2008/0471A patent/RS20080471A/sr unknown
- 2000-04-21 CN CNB2004100080411A patent/CN100360183C/zh not_active Expired - Fee Related
- 2000-04-21 TR TR2002/00027T patent/TR200200027T2/xx unknown
- 2000-04-21 KR KR1020077022430A patent/KR20070102760A/ko not_active Withdrawn
- 2000-04-21 EP EP00926238A patent/EP1173201B1/en not_active Expired - Lifetime
- 2000-04-21 CZ CZ20013754A patent/CZ301636B6/cs not_active IP Right Cessation
- 2000-04-21 DE DE60020955T patent/DE60020955T2/de not_active Expired - Lifetime
- 2000-04-21 NZ NZ515053A patent/NZ515053A/xx not_active IP Right Cessation
- 2000-04-21 PT PT00926238T patent/PT1173201E/pt unknown
- 2000-04-21 CN CNB008084548A patent/CN1191860C/zh not_active Expired - Fee Related
- 2000-04-21 DK DK00926238T patent/DK1173201T3/da active
- 2000-04-21 RS YUP-749/01A patent/RS50086B/sr unknown
- 2000-04-21 PL PL351916A patent/PL198975B1/pl unknown
- 2000-04-21 SK SK1520-2001A patent/SK287328B6/sk not_active IP Right Cessation
- 2000-04-21 EE EEP200100549A patent/EE05662B1/xx not_active IP Right Cessation
- 2000-04-21 JP JP2000613464A patent/JP5483515B2/ja not_active Expired - Fee Related
- 2000-04-21 CN CNB2005100044180A patent/CN1332714C/zh not_active Expired - Fee Related
- 2000-04-21 CA CA2370814A patent/CA2370814C/en not_active Expired - Fee Related
- 2000-04-21 AT AT00926238T patent/ATE298249T1/de active
- 2000-04-21 IL IL14589800A patent/IL145898A0/xx active IP Right Grant
- 2000-04-21 GE GE4588A patent/GEP20063844B/en unknown
- 2000-04-21 NZ NZ541431A patent/NZ541431A/en not_active IP Right Cessation
-
2001
- 2001-10-11 IS IS6105A patent/IS2259B/is unknown
- 2001-10-11 IL IL145898A patent/IL145898A/en not_active IP Right Cessation
- 2001-10-19 NO NO20015122A patent/NO330221B1/no not_active IP Right Cessation
- 2001-11-20 BG BG106118A patent/BG65578B1/bg unknown
-
2002
- 2002-02-01 US US10/061,658 patent/US6652856B2/en not_active Expired - Fee Related
-
2003
- 2003-07-22 US US10/625,260 patent/US20040037827A1/en not_active Abandoned
-
2005
- 2005-06-28 CY CY20051100768T patent/CY1106046T1/el unknown
- 2005-07-28 US US11/192,449 patent/US20050281818A1/en not_active Abandoned
-
2007
- 2007-03-26 JP JP2007080371A patent/JP2007182453A/ja active Pending
- 2007-05-01 IL IL182908A patent/IL182908A/en not_active IP Right Cessation
-
2008
- 2008-04-18 BG BG10110115A patent/BG66149B1/bg unknown
-
2010
- 2010-07-06 IL IL206829A patent/IL206829A/en not_active IP Right Cessation
- 2010-07-06 IL IL206830A patent/IL206830A/en not_active IP Right Cessation
-
2014
- 2014-01-20 JP JP2014007898A patent/JP2014065747A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hofheinz et al. | Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer | |
| JP5992843B2 (ja) | 抗ＩＬ−１α抗体による癌の処置方法 | |
| EP3689370B1 (en) | Anti-gdf15 antibodies | |
| ES2346184T3 (es) | Antagonistas de cd30 o cd30l para usar en el tratamiento de enfermedades antiinflamatorias cronicas y autoinmunes. | |
| JP5642683B2 (ja) | 安定な液体抗体配合物 | |
| JP7527386B2 (ja) | 新型コロナウイルスのヒトモノクローナル抗体およびその使用 | |
| JP2020536109A5 (cg-RX-API-DMAC7.html) | ||
| US9394362B2 (en) | IL-21 antibodies and methods of making or using the antibodies | |
| JP2007536932A5 (cg-RX-API-DMAC7.html) | ||
| JP2012501648A5 (cg-RX-API-DMAC7.html) | ||
| JP2018535948A5 (cg-RX-API-DMAC7.html) | ||
| JP2009155335A (ja) | 抗癌療法のためのマクロファージマイグレーション阻害因子アンタゴニストの使用 | |
| CN111153988B (zh) | 广谱抗肠道病毒d68型的中和性单克隆抗体 | |
| JP2011006464A (ja) | 喘息の治療における抗−ＴＮＦα抗体 | |
| JP2018532715A (ja) | 抗ｔｆ抗体薬物コンジュゲートの投薬レジメン | |
| WO2011137687A1 (zh) | 一种抗癌胚抗原抗体及其应用 | |
| JP2009521956A5 (cg-RX-API-DMAC7.html) | ||
| CA2370814A1 (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| JP2019512472A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535797A5 (cg-RX-API-DMAC7.html) | ||
| JP2014501513A5 (cg-RX-API-DMAC7.html) | ||
| JP2010521139A5 (cg-RX-API-DMAC7.html) | ||
| CN117603358B (zh) | 一种广谱新型冠状病毒的双特异性抗体 | |
| KR102769405B1 (ko) | Igfbp-3 및 그것의 수용체와 관련되는 질환의 치료 | |
| JP7660507B2 (ja) | レプチン受容体、ｇｄｆ８、およびアクチビンａに対するアンタゴニストを使用して、体重および除脂肪筋肉量を増やすための組成物および方法 |